thymalfasin (thymosin alpha 1) — Competitive Intelligence Brief

thymalfasin (thymosin alpha 1) (thymalfasin (thymosin alpha 1)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology.

phase 3 Immunomodulator T cell receptor Immunology Small molecule

Target snapshot

thymalfasin (thymosin alpha 1) (thymalfasin (thymosin alpha 1)) — SciClone Pharmaceuticals. Thymalfasin (thymosin alpha 1) is a peptide that stimulates the immune system by activating T cells and natural killer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
thymalfasin (thymosin alpha 1) TARGET	thymalfasin (thymosin alpha 1)	SciClone Pharmaceuticals	phase 3	Immunomodulator	T cell receptor
Glatiramer acetate (Copaxone)	Glatiramer acetate (Copaxone)	Federal University of São Paulo	marketed	Immunomodulator; disease-modifying therapy (DMT)	T cell receptor (indirect); myelin basic protein mimic
Vγ2Vδ2 T lymphocyte-based immunotherapy	Vγ2Vδ2 T lymphocyte-based immunotherapy	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Cell-based immunotherapy	Vγ2Vδ2 T cell receptor; phosphoantigens and stress-induced ligands
Copaxone-Teva	Copaxone-Teva	Biocad	phase 3	Immunomodulator; synthetic polypeptide	T cell receptor (indirect); myelin basic protein mimic
Glatiramer Acetate (GTR)	Glatiramer Acetate (GTR)	Synthon BV	phase 3	Immunomodulator; synthetic polypeptide	T cell receptor (indirect); myelin-reactive B and T cells
Glatiramer Acetate (DB)	Glatiramer Acetate (DB)	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Immunomodulator; synthetic polypeptide	T cell receptor (indirect); myelin basic protein mimic
Ganoderma lucidum	Ganoderma lucidum	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Herbal/botanical immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

1. Actavis Mid-Atlantic LLC · 1 drug in this class
2. Active Biotech AB · 1 drug in this class
3. Air Force Military Medical University, China · 1 drug in this class
4. Astellas Pharma Inc · 1 drug in this class
5. Bayer · 1 drug in this class
6. Beijing Children's Hospital · 1 drug in this class
7. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
8. Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
9. Chang Gung Memorial Hospital · 1 drug in this class
10. ALK-Abelló A/S · 1 drug in this class